A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
Blasco
Hélène
H
Boisdron-Celle
Michéle
M
Bougnoux
Philippe
P
Calais
Gilles
G
Tournamille
Jean-François
JF
Ciccolini
Joseph
J
Autret-Leca
Elisabeth
E
Le Guellec
Chantal
C
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D054067:Dihydropyrimidine Dehydrogenase Deficiency / Q000235:genetics*; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D011110:Polymorphism, Genetic / Q000235:genetics
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil